相关实验视频

Updated: Jun 23, 2025

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

简单语言的FOENIX-CCA2研究的摘要:富图巴提尼布用于晚期胆道癌症患者

Lipika Goyal¹, Funda Meric-Bernstam², Antoine Hollebecque³

¹Department of Medicine, Stanford University School of Medicine, & the Stanford Cancer Center, Palo Alto, CA, USA.

Future oncology (London, England)

|June 17, 2024

概括

在患有FGFR2基因变异的晚期胆道癌症患者中,futibatinib显著缩小了瘤. 在FOENIX-CCA2试验中,这种向治疗改善了整体生存率和生活质量.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
临床试验临床试验

背景情况:

晚期肝内胆管癌 (iCCA) 的预后不好,在疾病进展后经常需要化疗.
FGFR2基因融合是iCCA患者的一个子集中的关键驱动因素,代表了可向的脆弱性.
之前的治疗方法对晚期iCCA患者提供了有限的生存益处.

研究的目的:

评估futubatinib在患有FGFR2基因融合的晚期肝内胆管癌 (iCCA) 患者中的疗效.
评估futubatinib对瘤缩,无进展生存率和整体生存率的影响.
分析futubatinib治疗期间的安全性和患者报告的生活质量.

主要方法:

第2期临床试验 (FOENIX-CCA2) 评估futubatinib在先前接受治疗的先进iCCA的患者中.
通过客观反应率 (ORR) 和反应持续时间 (DoR) 评估瘤反应.
总生存率 (OS),无进展生存率 (PFS),安全性和生活质量 (QoL) 是关键的终点.

主要成果:

富提巴提尼布显示出显著的瘤缩,客观响应率 (ORR) 为42%和9.7个月的中位数无进展生存期 (PFS).
平均整体存活期 (OS) 为21.7个月,其中72%的患者在1年后还活着.
通过剂量调整可以控制不良事件,大多数患者维持或改善生活质量.

结论:

富提巴提尼布是一种有效的向疗法,用于患有晚期iCCA和FGFR2基因融合的患者.
该药物具有显著的临床益处,包括瘤减少和改善生存结果.
富提巴提尼布已经获得了美国,欧洲和日本的监管批准.

关键词:

胆性瘤是一种胆性瘤.没有Futibatinib.第二阶段第二阶段

更多相关视频

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor

Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor

Published on: January 4, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...